| Formulary Chapter 2: Cardiovascular system - Full Section
|
| Useful Links |
 Local Process for warfarin to DOAC switch_April 2020 |
|
Atrial fibrillation anticoagulant clinical decision aid for use in Primary Care |
|
DOAC Counselling Checklist |
|
National Guidance: Warfarin to DOAC switching _ April 2020 |
|
Warfarin to DOAC switching _ Local Guidance _ April 2020 |
|
NICE CG187: Acute heart failure: diagnosis and management |
 UKMI: MI - secondary prevention - Summary of NICE guidance (CG172) |
| Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
|
|
02.01 |
Positive inotropic drugs
(0,0)
|
|
02.01.01 |
Cardiac glycosides
(1,3)
|
|
|
Digoxin-specific antibody
(1,0)
|
|
02.01.02 |
Phosphodiesterase type-3 inhibitors
(1,1)
|
|
02.02.01 |
Thiazides and related diuretics
(6,2)
|
|
02.02.02 |
Loop diuretics
(2,2)
|
|
02.02.03 |
Potassium-sparing diuretics and aldosterone antagonists
(2,0)
|
|
|
Aldosterone antagonists
(2,0)
|
|
02.02.04 |
Potassium-sparing diuretics with other diuretics
(3,5)
|
|
02.02.05 |
Osmotic diuretics
(1,0)
|
|
02.02.06 |
Mercurial diuretics
(0,0)
|
|
02.02.07 |
Carbonic anhydrase inhibitors
(0,0)
|
|
02.02.08 |
Diuretics with potassium
(0,5)
|
|
02.03 |
Anti-arrhythmic drugs
(0,0)
|
|
02.03.01 |
Management of arrhythmias
(0,0)
|
|
02.03.02 |
Drugs for arrhythmias
(1,0)
|
|
|
Supraventricular arrhythmias
(2,0)
|
|
|
Supraventricular and ventricular arrhythmias
(5,1)
|
|
|
Ventricular arrhythmias
(1,1)
|
|
02.04 |
Beta-adrenoceptor blocking drugs
(9,14)
|
|
02.05 |
Drugs affecting the renin-angiotensin system and some other antihypertensive drugs
(0,0)
|
|
02.05.01 |
Vasodilator antihypertensive drugs
(13,1)
|
|
02.05.02 |
Centrally acting antihypertensive drugs
(2,2)
|
|
02.05.03 |
Adrenergic neurone blocking drugs
(0,1)
|
|
02.05.04 |
Alpha-adrenoceptor blocking drugs
(2,3)
|
|
|
Phaeochromocytoma
(2,0)
|
|
02.05.05 |
Drugs affecting the renin-angiotensin system
(0,1)
|
|
02.05.05.01 |
Angiotensin-converting enzyme inhibitors (ACE inhibitors)
(5,15)
|
|
02.05.05.02 |
Angiotensin-II receptor antagonists
(5,5)
|
|
02.05.05.03 |
Renin inhibitors
(0,2)
|
|
02.06.01 |
Nitrates
(5,2)
|
|
02.06.02 |
Calcium-channel blockers
(8,5)
|
|
02.06.03 |
Other anitanginal drugs
(3,0)
|
|
02.06.04 |
Peripheral vasodilators and related drugs
(2,3)
|
|
02.07 |
Sympathomimetics
(0,0)
|
|
02.07.01 |
Inotropic sympathomimetics
(4,0)
|
|
02.07.02 |
Vasoconstrictor sympathomimetics
(5,0)
|
|
02.07.03 |
Cardiopulmonary resuscitation
(1,0)
|
|
02.08 |
Anticoagulants and protamine
(1,1)
|
|
02.08.01 |
Parenteral anticoagulants
(1,0)
|
|
|
Heparin
(1,0)
|
|
|
Low molecular weight heparins
(3,0)
|
|
|
Heparinoids
(1,0)
|
|
|
Hirudins
(1,0)
|
|
|
Heparin flushes
(1,0)
|
|
|
Epoprostenol
(1,0)
|
|
|
Fondaparinux
(1,0)
|
|
02.08.02 |
Oral anticoagulants
(7,0)
|
|
|
Atrial Fibrillation
(0,0)
|
|
|
VTE treatment
(0,0)
|
|
|
VTE prophylaxis in hip/knee surgery
(0,0)
|
|
|
VTE Prophylaxis
(0,0)
|
|
02.08.03 |
Protamine sulphate
(1,0)
|
|
02.09 |
Antiplatelet drugs
(8,2)
|
|
02.10 |
Stable angina, acute coronary syndromes, and fibrinolysis
(0,0)
|
|
02.10.01 |
Management of stable angina and acute coronary syndromes
(0,0)
|
|
02.10.02 |
Fibrinolytic drugs
(5,0)
|
|
02.11 |
Antifibrinolytic drugs and haemostatics
(5,4)
|
|
|
Blood-related products
(0,0)
|
|
02.12 |
Lipid-regulating drugs
(0,2)
|
|
|
Statins
(4,1)
|
|
|
Bile acid sequestrants
(0,3)
|
|
|
Ezetimibe
(1,0)
|
|
|
Fibrates
(2,2)
|
|
|
Nicotinic acid group
(1,1)
|
|
|
Omega-3 fatty acid compounds
(0,1)
|
|
|
PCSK9 inhibitors
(2,0)
|
|
|
Other lipid modifying agents
(0,0)
|
|
02.13 |
Local sclerosants
(1,0)
|
